Related Experiment Video

Updated: May 17, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Induction of cell senescence by targeting to Cullin-RING Ligases (CRLs) for effective cancer therapy

Yongfu Pan1, Hua Xu, Rujiao Liu

  • 1Department of Immunology, Shanghai Medical College, Fudan University Shanghai 200032, China.

International Journal of Biochemistry and Molecular Biology
|October 26, 2012
PubMed

Insights

Targeting Cullin-RING ligases (CRLs) with genetic or pharmaceutical methods induces cellular senescence, a potent anticancer mechanism. This approach shows promise for cancer therapy by triggering cancer cell death.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Cullin-RING ligases (CRLs) are crucial multiunit ubiquitin E3 ligases regulating vital cellular processes like cell cycle, signal transduction, and growth.
  • Dysfunctional CRLs are implicated in various diseases, notably cancer, presenting CRLs as a therapeutic target.

Purpose of the Study:

  • To summarize the induction of cellular senescence as an anticancer mechanism by targeting CRLs.
  • To elucidate the mechanisms through which CRL targeting triggers cancer cell death.

Main Methods:

  • Review of studies involving genetic inactivation (siRNA, knockout) and pharmaceutical inhibition of specific CRL subunits.
  • Analysis of in vitro and in vivo data demonstrating anticancer effects.

Main Results:

  • Targeting CRLs activates multiple cell-killing pathways, including cellular senescence.
  • Inactivation of CRLs via various methods exhibits significant anticancer effects.

Conclusions:

  • Targeting CRLs, particularly through induction of cellular senescence, represents a promising strategy for cancer therapy.
  • Further research into CRL-targeting agents could lead to novel anticancer treatments.
Keywords:
CRLsMLN4924RBX1/ROC1Skp2cullin neddylationsenescence

More Related Videos

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells08:56

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells

Published on: July 12, 2022

Induction and Validation of Cellular Senescence in Primary Human Cells08:18

Induction and Validation of Cellular Senescence in Primary Human Cells

Published on: June 20, 2018

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Replicative Cell Senescence02:15

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
Replicative Cell Senescence02:15

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...